瑞普生物(300119.SZ)公告称，公司及全资子公司近日获得农业农村部核发的两款《新兽药注册证书》。第一款为禽腺病毒（I群，4型）蛋黄抗体，主要用于预防和治疗由I群4型禽腺病毒引起的鸡心包积液-肝炎综合征，具有中和病毒、缓解肝细胞坏死与心包积液、促进器官功能恢复等作用。第二款为青霉素V钾可溶性粉，主要用于治疗由产气荚膜梭菌引起的鸡坏死性肠炎，具有1日休药期和0日弃蛋期的核心优势，能有效降低药物残留风险、保障鸡肉食品安全。
瑞普生物(300119.SZ)公告称，公司及全资子公司近日获得农业农村部核发的两款《新兽药注册证书》。第一款为禽腺病毒（I群，4型）蛋黄抗体，主要用于预防和治疗由I群4型禽腺病毒引起的鸡心包积液-肝炎综合征，具有中和病毒、缓解肝细胞坏死与心包积液、促进器官功能恢复等作用。第二款为青霉素V钾可溶性粉，主要用于治疗由产气荚膜梭菌引起的鸡坏死性肠炎，具有1日休药期和0日弃蛋期的核心优势，能有效降低药物残留风险、保障鸡肉食品安全。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.